29,559 Shares in Lexicon Pharmaceuticals, Inc. $LXRX Purchased by R Squared Ltd

R Squared Ltd acquired a new position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 29,559 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of LXRX. AQR Capital Management LLC acquired a new stake in Lexicon Pharmaceuticals during the first quarter worth about $541,000. Monaco Asset Management SAM acquired a new stake in Lexicon Pharmaceuticals during the first quarter worth about $338,000. Acadian Asset Management LLC acquired a new stake in Lexicon Pharmaceuticals during the first quarter worth about $263,000. Compagnie Lombard Odier SCmA raised its stake in Lexicon Pharmaceuticals by 200.0% during the second quarter. Compagnie Lombard Odier SCmA now owns 330,000 shares of the biopharmaceutical company’s stock worth $312,000 after acquiring an additional 220,000 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Lexicon Pharmaceuticals by 173.5% in the first quarter. Invesco Ltd. now owns 285,759 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 181,265 shares during the period. Institutional investors and hedge funds own 74.70% of the company’s stock.

Analyst Upgrades and Downgrades

LXRX has been the topic of several analyst reports. Wall Street Zen upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, October 4th. Citigroup raised their price target on shares of Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the company a “buy” rating in a research note on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Saturday. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Tuesday, September 2nd. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.23.

Lexicon Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:LXRX opened at $1.42 on Monday. The stock has a market capitalization of $516.03 million, a price-to-earnings ratio of -4.30 and a beta of 1.23. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.28 and a 1-year high of $2.08. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.16 and a current ratio of 4.16. The company has a 50 day moving average price of $1.27 and a 200 day moving average price of $0.98.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The business had revenue of $28.87 million during the quarter, compared to the consensus estimate of $4.87 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. On average, research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.